Jove
Visualize
Contact Us

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

550
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
550
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

612
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
612
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

381
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
381
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

836
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
836
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

505
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
505
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

1.2K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Feasibility data from a novel laboratory model of spontaneous opioid withdrawal.

Experimental and clinical psychopharmacology·2026
Same author

Pulvinar responsive neurostimulation for posterior quadrant epilepsy: an illustrative case with connectome projection.

Neurosurgical review·2025
Same author

Prescribing Practices of Antiseizure Medications at US Academic Medical Centers for Pregnant People With and Without Epilepsy.

Neurology·2025
Same author

Author Correction: Metagenome analysis using the Kraken software suite.

Nature protocols·2024
Same author

The estrous cycle has no effect on incubation of methamphetamine craving and associated Fos expression in dorsomedial striatum and anterior intralaminar nucleus of thalamus.

Addiction neuroscience·2024
Same author

CHESS 3: an improved, comprehensive catalog of human genes and transcripts based on large-scale expression data, phylogenetic analysis, and protein structure.

Genome biology·2023
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Oct 30, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.2K

Neuromodulation in Drug Resistant Epilepsy.

Natalia Rincon1, Donald Barr1, Naymee Velez-Ruiz1

  • 1Department of Neurology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.

Aging and Disease
|July 5, 2021
PubMed
Summary

Drug-resistant epilepsy affects millions globally. Neuromodulation therapies like vagal nerve stimulation (VNS), responsive neurostimulation (RNS), and deep brain stimulation (DBS) offer alternative treatments for patients unsuitable for surgery.

Keywords:
DBSRNSVNSdrug-resistant epilepsyepilepsyneuromodulationneurostimulation

More Related Videos

Recording and Modulation of Epileptiform Activity in Rodent Brain Slices Coupled to Microelectrode Arrays
10:24

Recording and Modulation of Epileptiform Activity in Rodent Brain Slices Coupled to Microelectrode Arrays

Published on: May 15, 2018

14.9K
Author Spotlight: Unraveling Neural Communication and Circuit Interactions in Health and Disease
06:55

Author Spotlight: Unraveling Neural Communication and Circuit Interactions in Health and Disease

Published on: November 21, 2024

958

Related Experiment Videos

Last Updated: Oct 30, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.2K
Recording and Modulation of Epileptiform Activity in Rodent Brain Slices Coupled to Microelectrode Arrays
10:24

Recording and Modulation of Epileptiform Activity in Rodent Brain Slices Coupled to Microelectrode Arrays

Published on: May 15, 2018

14.9K
Author Spotlight: Unraveling Neural Communication and Circuit Interactions in Health and Disease
06:55

Author Spotlight: Unraveling Neural Communication and Circuit Interactions in Health and Disease

Published on: November 21, 2024

958

Area of Science:

  • Neurology
  • Neurosurgery

Background:

  • Epilepsy impacts 70 million worldwide, a major neurological disorder.
  • Drug-resistant epilepsy affects 30-40% of people with epilepsy (PWE) despite new antiepileptic drugs (AEDs).
  • Many drug-resistant epilepsy patients are ineligible for curative surgery due to seizure focus location or multifocal epilepsy.

Purpose of the Study:

  • To review evidence, indications, and safety of neuromodulation therapies for drug-resistant epilepsy.
  • To highlight neuromodulation as an alternative for patients who are poor surgical candidates.

Main Methods:

  • Review of existing literature on neuromodulation therapies.
  • Focus on vagal nerve stimulation (VNS), responsive neurostimulation (RNS), and deep brain stimulation (DBS).

Main Results:

  • Neuromodulation presents viable treatment options for specific epilepsy cases.
  • Evidence supports VNS, RNS, and DBS for managing drug-resistant epilepsy.
  • Safety considerations for these advanced therapies are discussed.

Conclusions:

  • Neuromodulation offers hope for patients with drug-resistant epilepsy who cannot undergo surgery.
  • VNS, RNS, and DBS are key alternative treatment modalities.
  • Comprehensive evaluation is crucial to determine suitability for neuromodulation therapies.